Pyxis Oncology, Inc.
PYXSHealthcare|Biotechnology|US
$1.66
+0.05 (+3.11%)
DCF Value
$1.70
Tangible Book / Share
$0.49
Cash / Share
$0.67
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06795412 Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors | Advanced Solid Tumors | P1P2 | Recruiting | 220 | Open-label | PYX-201, pembrolizumab |
| NCT05718557 Study of PYX-106 in Solid Tumors | Solid Tumor | P1 | Active | 47 | Open-label | PYX-106 |
| NCT05720117 A Study of PYX-201 in Advanced Solid Tumors | Solid Tumor, Advanced Solid Tumor | P1 | Recruiting | 330 | Open-label | PYX-201 |
| NCT02706353 APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma | Melanoma | P1P2 | Terminated | 34 | Open-label | APX005M, Pembrolizumab |
| NCT03389802 Phase I Study of APX005M in Pediatric Central Nervous System Tumors | Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS) | P1 | Completed | 32 | Open-label | APX005M treatment for recurrent or refractory primary malignant CNS tumor patients, APX005M treatment for newly diagnosed DIPG patients |